Summary of COVID-19 SA58 studies

1. Song et al., Post-exposure prophylaxis with SA58 (anti-SARS-COV-2 monoclonal antibody) nasal spray for the prevention of symptomatic COVID-19 in healthy adult workers: a randomized, single-blind, placebo-controlled clinical study

1,123 patient SA58 prophylaxis RCT: 81% fewer symptomatic cases (p=0.0004) and 62% fewer cases (p=0.0001).
RCT 1,222 healthy adult workers in China showing SA58 (anti-SARS-CoV-2 monoclonal antibody) nasal spray reduced symptomatic COVID-19 by 81% and SARS-COV-2 infection by 62% compared to placebo when used as post-exposure prophylaxis within 72 hours of exposure. Efficacy was significantly lower when including participants who tested positive within 24 hours of first administration, suggesting SA58 is less effective once infection is established.
May 2023, Emerging Microbes & Infections, https://www.tandfonline.com/doi/full/10.1080/22221751.2023.2212806, https://c19p.org/song9

2. Si et al., Safety and Effectiveness of SA58 Nasal Spray Against COVID-19 Infection in Medical Personnel: An Open-Label, Blank-Controlled Study — Hohhot City, Inner Mongolia Autonomous Region, China, 2022

3,368 patient SA58 prophylaxis study: 78% fewer cases (p=0.0001).
Prospective study of 3,368 medical personnel in China showing significantly lower COVID-19 cases with SA58 nasal spray use.
Dec 2023, China CDC Weekly, https://weekly.chinacdc.cn/en/article/doi/10.46234/ccdcw2023.040, https://c19p.org/si

3. Wang et al., Safety and Effectiveness of SA58 Nasal Spray against SARS-CoV-2 family transmission: an exploratory single-arm trial

432 patient SA58 prophylaxis study: 34% fewer cases (p<0.0001).
Exploratory single-arm trial of 70 family contacts showing a protective effect of SA58 nasal spray against household SARS-CoV-2 transmission. The incidence of infection was 62.9% in the experimental group versus 94.8% in a contemporaneous control group (n=362), suggesting that SA58 nasal spray reduced transmission risk by 33.8% overall. Using SA58 at least three times daily showed better protection than once a day.
Mar 2023, medRxiv, https://www.medrxiv.org/content/10.1101/2023.03.19.23287462, https://c19p.org/wang46

Submit Corrections or Updates

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.

Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0